Decline in Patient Visits and Contract Processing Volumes Due to COVID-19
First written in FY2020-Q2. 9 of 11 entries say "Mitigated", first in FY2020-Q3. Latest entry: FY2025.
CellSource moved to the "Worse" side of this theme in 2026, 6 years after the typical company in this theme (2020).
1 other company's latest entry also says "Reframed".
- FY2025ReframedAnnual report
「If demand in regenerative medicine, biopharmaceuticals and other fields expands rapidly, transportation conditions become a concern due to international circumstances, or an event similar to COVID-19 occurs, shortages of materials could delay or halt outsourced processing services and have a material impact on the operating results and financial condition of our group.」
The risk has been reframed from the specific risk of declining patient visits and outsourced processing projects due to COVID-19 to the risk of material shortages and delays or suspensions of outsourced processing services, including in similar situations. - FY2022MitigatedAnnual report
「The number of outsourced processing projects was not significantly affected during the subsequent states of emergency or periods of renewed infection spread.」
Although patient visits and outsourced processing projects declined initially, it was disclosed that the subsequent resurgence of infections had no significant impact on the number of outsourced processing projects. - FY2022-Q3MitigatedAnnual report
「During the cumulative third quarter, the slowdown in sales growth caused by the spread of COVID-19 seen at the beginning of the period subsided, and the business expanded steadily, mainly through outsourced processing services.」
The slowdown in sales growth caused by the spread of infections at the beginning of the period subsided, and the business expanded, mainly through outsourced processing services. - FY2022-Q2MitigatedAnnual report
「During the cumulative second quarter, as the spread of COVID-19 subsided, the number of affiliated medical institutions and outsourced processing projects at our company began to increase, and sales expanded steadily, mainly from outsourced processing services.」
As the spread of COVID-19 subsided, the number of affiliated medical institutions and outsourced processing projects began to increase, and sales expanded, mainly from outsourced processing services. The impact of the spread of infections on the business was contained. - FY2022-Q1MitigatedAnnual report
「During the cumulative first quarter, quasi-emergency measures were applied in multiple prefectures, including Tokyo, due to the renewed spread of COVID-19. However, at our company, the number of affiliated medical institutions and outsourced processing projects continued to grow steadily, and sales expanded steadily, mainly from outsourced processing services.」
Despite the renewed spread of infections and the application of quasi-emergency measures, the number of affiliated medical institutions and outsourced processing projects grew, and sales expanded, mainly from outsourced processing services. The impact of the spread of infections on the business was contained during the quarter. - FY2021MitigatedAnnual report
「The number of outsourced processing projects was not significantly affected during the subsequent states of emergency or periods of renewed infection spread.」
Although the number of outsourced processing projects declined during the initial phase of the spread of infections, it was disclosed that the subsequent states of emergency and renewed infection spread had no significant impact. - FY2021-Q2MitigatedAnnual report
「During the cumulative second quarter, the resurgence of COVID-19 led to states of emergency being declared or quasi-emergency measures being applied in multiple prefectures, including Tokyo. However, at our company, the number of affiliated medical institutions and outsourced processing projects continued to grow steadily, and sales expanded steadily, mainly from outsourced processing services.」
Despite the resurgence of COVID-19 and the declaration of states of emergency and other measures, the number of affiliated medical institutions and outsourced processing projects grew, and sales expanded, mainly from outsourced processing services. The impact of the spread of infections on the business was contained during the quarter. - FY2021-Q1MitigatedAnnual report
「During the cumulative first quarter, the third wave of COVID-19 led to states of emergency being declared in Tokyo and certain other prefectures, but at our company, the number of affiliated medical institutions and outsourced processing projects continued to grow steadily, and sales expanded steadily, mainly from outsourced processing services.」
Despite the resurgence of the third wave of COVID-19 and the declaration of a state of emergency, the number of affiliated medical institutions and outsourced processing projects grew, indicating that the impact on the business was contained. - FY2020MitigatedAnnual report
「Since March 2020, the first wave of COVID-19 infections reduced patient visits to our affiliated medical institutions, resulting in a decline in the number of outsourced processing projects. However, since the state of emergency was lifted in May of that year, the number of outsourced processing projects has recovered and grown steadily, and the second and third waves had no significant impact on the number of projects.」
It was disclosed that, following a decline in patient visits and outsourced processing projects during the first wave, the number of projects recovered and grew, while the second and third waves had no significant impact. - FY2020-Q3MitigatedAnnual report
「Since March 2020, the spread of COVID-19 has reduced patient visits to our affiliated medical institutions, resulting in a decline in the number of outsourced processing projects in our regenerative medicine-related business. Although the number of outsourced processing projects has been recovering since the state of emergency was lifted in May of that year, a prolonged resurgence of COVID-19 infections could again cause deterioration in earnings from our regenerative medicine-related business and affect our operating results and financial condition.」
The decline in patient visits and outsourced processing projects caused by the spread of COVID-19 continued, but the number of outsourced processing projects recovered after the state of emergency was lifted. The risk of a prolonged resurgence continues to be disclosed. - FY2020-Q2First statedAnnual report
「As the COVID-19 pandemic spread, the number of patients visiting the company's affiliated medical institutions declined, and the number of processing contracts in the regenerative medicine-related business decreased. Although the number of processing contracts has shown signs of recovery since the lifting of the state of emergency and the company considers this decline temporary, if the decline is prolonged due to a resurgence of COVID-19 or other factors, it could affect the company's operating results and financial condition through deterioration in earnings from the regenerative medicine-related business.」
Declines in patient visits and processing contracts were added as a new risk that had actually materialized. The number of contracts declined from 1,922 in the first quarter accounting period to 1,559 in the second quarter accounting period, although a recovery trend since the lifting of the state of emergency was also noted.